Back
ESC Premium Access

Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

Session: Progress in secondary prevention - New treatments
Topic: Drug therapy
Speaker: Doctor R. Diaz (Rosario, AR)
Event: ESC Congress 2019

Congress Presentation

About the speaker

Doctor Rafael Diaz

Estudios Cardiologicos Latinoamerica (ECLA), Rosario (Argentina)
2 presentations
0 follower

4 more presentations in this session

Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis

Speaker: Mr A. Roddick (Oxford, GB)

Access
Abstract
Slides
Video
Thumbnail

Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial

Speaker: Doctor T. Vanassche (Leuven, BE)

Access
Abstract
Slides
Video
Thumbnail

Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials

Speaker: Miss O. Ghosh-Swaby (London, CA)

Access
Abstract
Slides
Video
Thumbnail

Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy

Speaker: Professor M. Roe (Chapel Hill, US)

Access
Abstract
Slides
Video
Thumbnail

Access the full session

Progress in secondary prevention - New treatments

Speakers: Doctor R. Diaz, Mr A. Roddick, Doctor T. Vanassche, Miss O. Ghosh-Swaby, Professor M. Roe
Access
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb